Frost & Sullivan Reveal Asia as Ideal Trial Destination

Article

Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials.

Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials. The report states that this result is due to vast treatment-naive patient pools, clinical infrastructure and low operational costs.

Read the full report here

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.